keyword
MENU ▼
Read by QxMD icon Read
search

Quetiapine dosing

keyword
https://www.readbyqxmd.com/read/29649903/pharmacokinetic-evaluation-of-quetiapine-fumarate-controlled-release-hybrid-hydrogel-a-healthier-treatment-of-schizophrenia
#1
Muhammad Akhlaq, Faiza Maryam, Abdelhamid Elaissari, Hashmat Ullah, Muhammad Adeel, Abid Hussain, Muhammad Ramzan, Obaid Ullah, Muhammad Zeeshan Danish, Shehla Iftikhar, Nighat Aziz
The current study aimed to rationally develop and characterize pH-sensitive controlled release hydrogels by graft polymerization of gelatin (Gel) and hydroxypropyl methyl cellulose (HPMC) in the presence of glutaraldehyde (GA) using quetiapine fumarate for the treatment of schizophrenia. The prepared hydrogels discs were subjected to various physicochemical studies including: swelling, diffusion, porosity, sol-gel analysis, Fourier transform infrared spectroscopy, differential scanning calorimetry, and scanning electron microscopy...
November 2018: Drug Delivery
https://www.readbyqxmd.com/read/29593414/a-low-dose-of-risperidone-resolved-charles-bonnet-syndrome-after-an-unsuccessful-trial-of-quetiapine-a-case-report
#2
Sultan H Alamri
Charles Bonnet syndrome (CBS) is a diagnosis of exclusion. Typical affected patients have impaired visual acuity, vivid recurring visual hallucinations, and no cognitive impairment. Vision loss is most commonly due to macular degeneration, although many other causes exist. Here, we report a case of an 87-year-old woman with CBS and discuss the diagnosis and treatment.
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29575543/identifying-off-label-prescriptions-through-data-mining-in-danish-community-pharmacy-servers-an-exploratory-study-on-desmopressin-diclofenac-fucidin-mirtazapine-and-quetiapine
#3
Monika Andrulyte, Ole Jannik Bjerrum
The term off-label use describes the prescription and administration of medicines outside of the terms for which it officially has been approved, including age, dose and indication. Off-label data can be generated from the Danish National Prescription Registry (DNPR) through combinations with diagnoses, however the community pharmacy servers provide equal, local, albeit less data through a faster and less constrained collection process. The data collection for this exploratory study took place at five community pharmacies in Denmark...
March 25, 2018: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29507281/differential-effect-of-quetiapine-and-lithium-on-functional-connectivity-of-the-striatum-in-first-episode-mania
#4
Orwa Dandash, Murat Yücel, Rothanthi Daglas, Christos Pantelis, Patrick McGorry, Michael Berk, Alex Fornito
Mood disturbances seen in first-episode mania (FEM) are linked to disturbed functional connectivity of the striatum. Lithium and quetiapine are effective treatments for mania but their neurobiological effects remain largely unknown. We conducted a single-blinded randomized controlled maintenance trial in 61 FEM patients and 30 healthy controls. Patients were stabilized for a minimum of 2 weeks on lithium plus quetiapine then randomly assigned to either lithium (serum level 0.6 mmol/L) or quetiapine (dosed up to 800 mg/day) treatment for 12 months...
March 6, 2018: Translational Psychiatry
https://www.readbyqxmd.com/read/29497196/oculogyric-crisis-with-atypical-antipsychotics-a-case-series
#5
Naresh Nebhinani, Navratan Suthar
Oculogyric crisis (OGC) is an acute dystonic reaction, commonly seen with the administration of typical antipsychotics, and rarely reported with atypical antipsychotics. Here, we report five cases of oculogyric crisis, developed after administration of atypical antipsychotics. The first case developed OGC on quetiapine 800 mg/day and the second case on olanzapine 20 mg/day. Both the patients did not improve on adding anticholinergic agents and finally stabilized by switching to clozapine. The third case developed OGC on amisulpride 400 mg and lurasidone 40 mg/day and improved by reducing amisulpride dose to 200 mg and stopping lurasidone...
October 2017: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/29494265/pharmacological-interventions-for-psychosis-in-parkinson-s-disease-patients
#6
Joseph H Friedman
Psychosis is a common problem for people treated for Parkinson's disease. The syndrome is quite stereotypic, with hallucinations being the most common, followed by delusions. While the hallucinations are usually not very bothersome, the delusions are typically paranoid in nature. Treatment is often, but not always, required. Areas covered: This article reviews the therapeutic approaches of this syndrome focusing on drug treatments used once contributory factors have been removed. This includes a review of the evidence supporting the use of clozapine and, most recently, pimavanserin, the first drug with antipsychotic efficacy that has no effect on dopamine...
March 1, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29493050/the-impact-of-permissive-and-restrictive-pharmaceutical-policies-on-quetiapine-dispensing-evaluating-a-policy-pendulum-using-interrupted-time-series-analysis
#7
Jonathan Brett, Andrea Schaffer, Timothy Dobbins, Nicholas A Buckley, Sallie-Anne Pearson
PURPOSE: To evaluate the impact of 2 policy changes on quetiapine dispensing in Australia: removal of prior authorisation for prescribing (policy 1: July 2007) and removal of repeat prescriptions for 25-mg quetiapine (policy 2: January 2014). METHODS: We performed an interrupted time series analysis using Pharmaceutical Benefits Scheme claims data (July 2005 to December 2015). We assessed the impact of both policies on monthly quetiapine dispensing (25 mg and >25 mg) and the impact of policy change 2 on monthly rates of 25-mg discontinuation and switching from 25 mg to other quetiapine strengths...
February 28, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29487083/drugs-for-insomnia-beyond-benzodiazepines-pharmacology-clinical-applications-and-discovery
#8
REVIEW
Tobias Atkin, Stefano Comai, Gabriella Gobbi
Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have many side effects, including cognitive impairment, tolerance, rebound insomnia upon discontinuation, car accidents/falls, abuse, and dependence liability. Consequently, the clinical use of off-label drugs and novel drugs that do not target the GABAergic system is increasing. The purpose of this review is to analyze the neurobiological and clinical evidence of pharmacological treatments of insomnia, excluding the BZDs and Z-drugs...
April 2018: Pharmacological Reviews
https://www.readbyqxmd.com/read/29477044/activation-of-phosphoinositide-3-kinase-delta-by-antipsychotic-drugs-preliminary-results
#9
Michał Seweryn Karbownik, Paweł Gunerka, Paweł Turowski, Maciej Wieczorek, Edward Kowalczyk, Wojciech Łężak, Tadeusz Pietras
BACKGROUND: Catalytic subunit delta of phosphoinositide 3-kinase, p110δ, encoded by the PIK3CD gene, was recently proposed as a target for pharmacological treatment of schizophrenia. Current antipsychotic drugs were found to decrease the mRNA expression of PIK3CD, but the mechanism of this process is not known. The aim of the study was to elucidate the mechanism by which antipsychotic drugs affect the mRNA expression of PIK3CD. METHODS: The direct effect of haloperidol, clozapine, olanzapine, quetiapine and amisulpride on p110δ enzymatic activity was tested with a kinase assay, and the results were referenced against data on the mRNA expression of PIK3CD...
September 20, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29453005/post-mortem-quetiapine-concentrations-in-hair-segments-of-psychiatric-patients-correlation-between-hair-concentration-dose-and-concentration-in-blood
#10
Kamilla Nyborg Günther, Sys Stybe Johansen, Marie Katrine Klose Nielsen, Petra Wicktor, Jytte Banner, Kristian Linnet
Drug analysis in hair is useful when seeking to establish drug intake over a period of months to years. Segmental hair analysis can also document whether psychiatric patients are receiving a stable intake of antipsychotics. This study describes segmental analysis of the antipsychotic drug quetiapine in post-mortem hair samples from long-term quetiapine users by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) analysis. The aim was to obtain more knowledge on quetiapine concentrations in hair and to relate the concentration in hair to the administered dose and the post-mortem concentration in femoral blood...
April 2018: Forensic Science International
https://www.readbyqxmd.com/read/29432503/therapeutic-drug-monitoring-of-atypical-antipsychotics
#11
REVIEW
Anna Emilia Urban, Wiesław Jerzy Cubała
The paper presents an overview and analysis of the results of research on therapeutic ranges of concentrations and receptor occupancy, mainly D2 receptors, in the treatment with some atypical antipsychotic drugs. Amisulpride, aripiprazole, clozapine, quetiapine, olanzapine, risperidone, paliperidone, sertindole, and ziprasidone were taken into account. The benefits of therapeutic drug monitoring to optimize the effectiveness of treatment and avoid side effects or toxicity were shown. The safety of patients, with the possibility to use the lowest effective dose, is an undoubted profit of TDM...
December 30, 2017: Psychiatria Polska
https://www.readbyqxmd.com/read/29410934/insight-and-treatment-outcomes-in-schizophrenia-post-hoc-analysis-of-a-long-term-double-blind-study-comparing-lurasidone-and-quetiapine-xr
#12
Philip D Harvey, Cynthia O Siu, Antony D Loebel
Objective: The objective of this post-hoc analysis was to evaluate the effect of lurasidone and quetiapine extended-release (XR) on insight and judgment and assess the longitudinal relationships between improvement in insight and cognitive performance, functional capacity, quality of well-being, and depressive symptoms in patients with schizophrenia. Design: Clinically unstable patients with schizophrenia (N=488) were randomized to once-daily, fixed-dose treatment with lurasidone 80mg, lurasidone 160mg, quetiapine XR 600mg, or placebo, followed by a long-term, double-blind, flexible-dose continuation study involving these agents...
December 1, 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29409162/antipsychotic-reduction-and-or-cessation-and-antipsychotics-as-specific-treatments-for-tardive-dyskinesia
#13
REVIEW
Hanna Bergman, John Rathbone, Vivek Agarwal, Karla Soares-Weiser
BACKGROUND: Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetitive involuntary movements around the mouth and face. Various strategies have been examined to reduce a person's cumulative exposure to antipsychotics. These strategies include dose reduction, intermittent dosing strategies such as drug holidays, and antipsychotic cessation...
February 6, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29401113/clozapine-for-treatment-refractory-behavioral-disturbance-in-dementia
#14
Andreea Teodorescu, Lorena Dima, Petru Ifteni, Liliana M Rogozea
BACKGROUND: Behavioral and psychological symptoms in dementia significantly contribute to caregiver burden and impose patient hospitalization. The goal of treatment of admitted patients is the rapid remission of symptoms to allow their return to home as soon as possible. Intervention requires an intrusive approach with parenteral treatment and physical restraints, with a negative emotional impact on patients and their families. Despite the large utilization of antipsychotics for behavioral and psychological symptoms, there is no antipsychotic approved by the Food and Drug Administration for agitation in dementia...
January 31, 2018: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29392351/determination-of-plasma-concentration-reference-ranges-for-oral-aripiprazole-olanzapine-and-quetiapine
#15
Julia Korell, Bruce Green, Allan Rae, Bart Remmerie, An Vermeulen
BACKGROUND: Schizophrenia is a common disease which is commonly managed using antipsychotic medications (APS). Inadequate response and lack of adherence often prevent optimal therapeutic effectiveness. Monitoring APS concentrations can be useful to help improve outcomes for the patient. AIMS: The aim of this study was to develop "reference ranges" for oral aripiprazole, olanzapine, and quetiapine to allow clinicians to understand expected variability in patients treated with APS...
February 1, 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29369597/how-long-does-the-pharmacokinetic-interaction-between-carbamazepine-and-quetiapine-last-after-carbamazepine-withdrawal
#16
(no author information available yet)
OBJECTIVES: Carbamazepine and quetiapine are drugs that are used as mood stabilizers in the treatment of bipolar disorders. A series of studies has shown that concurrent use of carbamazepine decreases quetiapine serum level due to induction of CYP3A enzymes by carbamazepine. METHODS: In a 30-year-old bipolar patient with mania treated with quetiapine 1200 mg and carbamazepine 900 mg per day, we measured quetiapine serum level before and after carbamazepine withdrawal...
December 25, 2017: Neuro Endocrinology Letters
https://www.readbyqxmd.com/read/29357776/comparison-of-lurasidone-versus-quetiapine-for-the-treatment-of-delirium-in-critically-ill-patients
#17
Marlena A Fox, Jessica L Elefritz, Brandon M Huang, Charles Hunley
OBJECTIVE: To evaluate the efficacy and safety of lurasidone compared with quetiapine for treatment of delirium in critically ill patients. DESIGN: Prospective, observational cohort study. SETTING: Single-center community teaching hospital. PATIENTS: Forty adult intensive care unit (ICU) patients with delirium (Confusion Assessment Method in the ICU positive), tolerating enteral nutrition, and without active alcohol withdrawal or prior use of atypical antipsychotics...
January 1, 2018: Journal of Intensive Care Medicine
https://www.readbyqxmd.com/read/29343128/efficacy-and-safety-of-flexibly-dosed-brexpiprazole-for-the-adjunctive-treatment-of-major-depressive-disorder-a-randomized-active-referenced-placebo-controlled-study
#18
Mary Hobart, Aleksandar Skuban, Peter Zhang, Mette Krog Josiassen, Nanco Hefting, Carole Augustine, Claudette Brewer, Raymond Sanchez, Robert D McQuade
OBJECTIVE: To assess the efficacy, safety, and tolerability of brexpiprazole as adjunctive treatment in adults with major depressive disorder (MDD) and an inadequate response to prior antidepressant treatment (ADT). METHODS: Patients with a current major depressive episode after prior treatment with 1-3 ADTs entered an 8- or 10-week prospective treatment phase in which they received double-blind placebo adjunct to open-label ADT. Inadequate responders were randomized (2:2:1) to brexpiprazole 2-3 mg/day, placebo, or quetiapine extended-release (XR) 150-300 mg/day, adjunct to the same ADT, for 6 weeks...
April 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29343085/a-lack-of-systemic-absorption-following-the-repeated-application-of-topical-quetiapine-in-healthy-adults
#19
Bryce Kayhart, Maria I Lapid, Sarah Nelson, Julie L Cunningham, Virginia H Thompson, Jonathan G Leung
In the absence of suitable oral or intravenous access for medication administration and when the intramuscular medications are undesirable, alternative routes for drug delivery may be considered. Antipsychotics administered via an inhaled, intranasal, rectal, or topical route have been described in the literature. Topically administered antipsychotics have been previously reported to produce negligible systemic absorption despite being used in clinical practice for nausea and behavioral symptoms associated with dementia...
January 1, 2018: American Journal of Hospice & Palliative Care
https://www.readbyqxmd.com/read/29331603/metabolic-risk-factors-in-schizophrenia-and-bipolar-disorder-the-effect-of-comedication-with-selective-serotonin-reuptake-inhibitors-and-antipsychotics
#20
K K Fjukstad, A Engum, S Lydersen, I Dieset, N Eiel Steen, O A Andreassen, O Spigset
BACKGROUND: The aim of this observational study was to investigate the relationship between metabolic factors and use of selective serotonin reuptake inhibitors (SSRIs) combined with olanzapine, quetiapine or risperidone. METHODS: Data from the Norwegian Thematically Organized Psychosis study, a cross-sectional study on 1301 patients with schizophrenia (n=868) or bipolar disorder (n=433), were analyzed. As exposure variables in the linear regression model were included the dose or serum concentration of SSRIs (n=280) and of olanzapine (n=398), quetiapine (n=234) or risperidone (n=128)...
February 2018: European Psychiatry: the Journal of the Association of European Psychiatrists
keyword
keyword
86415
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"